JP2008510705A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510705A5
JP2008510705A5 JP2007527993A JP2007527993A JP2008510705A5 JP 2008510705 A5 JP2008510705 A5 JP 2008510705A5 JP 2007527993 A JP2007527993 A JP 2007527993A JP 2007527993 A JP2007527993 A JP 2007527993A JP 2008510705 A5 JP2008510705 A5 JP 2008510705A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pde5 inhibitor
cardiac
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007527993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510705A (ja
JP5070052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/029327 external-priority patent/WO2006023603A2/en
Publication of JP2008510705A publication Critical patent/JP2008510705A/ja
Publication of JP2008510705A5 publication Critical patent/JP2008510705A5/ja
Application granted granted Critical
Publication of JP5070052B2 publication Critical patent/JP5070052B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2007527993A 2004-08-17 2005-08-17 Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法 Expired - Fee Related JP5070052B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60213404P 2004-08-17 2004-08-17
US60/602,134 2004-08-17
PCT/US2005/029327 WO2006023603A2 (en) 2004-08-17 2005-08-17 Pde5 inhibitor compositions and methods for treating cardiac indications

Publications (3)

Publication Number Publication Date
JP2008510705A JP2008510705A (ja) 2008-04-10
JP2008510705A5 true JP2008510705A5 (https=) 2008-10-23
JP5070052B2 JP5070052B2 (ja) 2012-11-07

Family

ID=35968156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527993A Expired - Fee Related JP5070052B2 (ja) 2004-08-17 2005-08-17 Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法

Country Status (7)

Country Link
US (1) US8299083B2 (https=)
EP (1) EP1786428B1 (https=)
JP (1) JP5070052B2 (https=)
CN (1) CN101106997A (https=)
AU (1) AU2005277384B2 (https=)
CA (1) CA2577442A1 (https=)
WO (1) WO2006023603A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841300B2 (en) * 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
CA2676422C (en) 2007-02-06 2018-10-16 Lixte Biotechnology Holdings, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
CN101754756A (zh) * 2007-05-18 2010-06-23 维瓦斯公司 包含磷酸二酯酶-5抑制剂的新组合和它们的用途
EA018618B1 (ru) 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
EP2922465A4 (en) 2012-11-21 2016-07-06 Cardiomems Inc DEVICES, SYSTEMS AND METHODS FOR ASSESSING AND TREATING PULMONARY ARTERIAL HYPERTENSION (PAH)
US9198908B2 (en) * 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
KR20190049691A (ko) * 2016-07-07 2019-05-09 카듀리온 파마슈티칼스, 엘엘씨 심부전의 치료 방법
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
EP3569249A4 (en) * 2016-12-27 2020-11-11 Osaka University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE
US20210386743A1 (en) * 2018-10-08 2021-12-16 The Johns Hopkins University Use of pde9 inhibitors for treatment
WO2025226615A1 (en) * 2024-04-22 2025-10-30 Huyabio International, Llc Sodium salt and ethanolamine salt of 23-hydroxytormentic acid

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
AU5427098A (en) 1996-11-04 1998-05-29 Johns Hopkins University, The Assessing cardiac contractility and cardiovascular interaction
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
US6723719B1 (en) 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
AU755361B2 (en) 1998-02-19 2002-12-12 Eisai R&D Management Co., Ltd. Phthalazine derivatives and remedies for erectile dysfunction
RS50011B (sr) * 1998-04-20 2008-09-29 Pfizer Inc., Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
IL144156A0 (en) 1999-01-20 2002-05-23 Dresden Arzneimittel Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6774128B2 (en) 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
JP2004501124A (ja) 2000-06-07 2004-01-15 リリー　アイコス　リミテッド　ライアビリティ　カンパニー 化合物
US6911542B2 (en) 2000-06-23 2005-06-28 Lilly Icos Llc. Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives
MXPA02012470A (es) 2000-06-23 2004-01-26 Lilly Icos Llc Inhibidores de fosfodiesterasa especificos para gmp ciclico.
MXPA02012659A (es) 2000-06-26 2003-09-22 Lilly Icos Llc Derivados de pirazindiona condensados.
DE60121461T2 (de) 2000-10-03 2007-02-08 Lilly Icos Llc, Wilmington Kondensierte pyridoindolderivate
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0129274D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
WO2003101276A2 (en) 2002-05-22 2003-12-11 Virginia Commonwealth University Protective effects of pde-5 inhibitors
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
AU2003286555A1 (en) 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2005012303A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

Similar Documents

Publication Publication Date Title
JP2008510705A5 (https=)
ES3014965T3 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
Maron Hypertrophic cardiomyopathy in childhood
US20080075666A1 (en) Methods and compositions for treating diastolic dysfunction
US20070042957A1 (en) Type v phosphodiesterase inhibitors and natriuretic polypeptides
Hartley et al. Doppler estimation of reduced coronary flow reserve in mice with pressure overload cardiac hypertrophy
Albaladejo et al. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats
WO2024020468A1 (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
Takaoka et al. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart
JP2008527003A (ja) 喘息又は気管支痙攣の既往歴を有する患者における心筋機能不全を検出する方法
Ratcliffe et al. Ventricular volume, chamber stiffness, and function after anteroapical aneurysm plication in the sheep
Provotorov et al. Endothelio-and cardioprotective effects of vitamin В6 and folic acid in modelling methionine-induced hyperhomocysteinemia
Zhang et al. Myocardial bioenergetics during acute hibernation
Pagel et al. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs
WO2020201263A1 (en) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
WO2009066085A1 (en) Treatment of heart failure with normal ejection fraction
CN114727951A (zh) 用于治疗房坦姑息术后患者中的肺血管疾病和/或心功能障碍的药物组合物
Sherrid et al. Medical treatment of hypertrophic cardiomyopathy
Busk et al. Effects of Levosimendan on Myocardial Infarct Size and Hemodynamics in a Closed-Chest Porcine Ischemia–Reperfusion Model
US12419863B2 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
Joyce et al. A direct comparison of right and left ventricular performance in the isolated neonatal pig heart
CHATTERJEE Newer oral inotropic agents: phosphodiesterase inhibitors
Terp et al. Functional remodelling and left ventricular dysfunction after repeated ischaemic episodes: a chronic experimental porcine model
FREED Cardiac Physiology
Goldberg et al. Transoesophageal atrial pacing stress echocardiography in coronary artery disease: role, principles and methodology